List of works - Martin Dyer

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity

scientific article

Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells

scientific article published on 13 April 2009

Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia

scientific article published on 29 July 2009

A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia

scientific journal article

The BCL11 gene family: involvement of BCL11A in lymphoid malignancies

scientific article published on December 1, 2001

The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.

scientific article

REMISSION INDUCTION IN NON-HODGKIN LYMPHOMA WITH RESHAPED HUMAN MONOCLONAL ANTIBODY CAMPATH-1H

scientific article published in The Lancet

Different forms of cell death induced by putative BCL2 inhibitors.

scientific article

Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk

scientific article published on 10 January 2010

CARD9 is a novel caspase recruitment domain-containing protein that interacts with BCL10/CLAP and activates NF-kappa B

scientific article

Clustering of missense mutations in the ataxia-telanglectasia gene in a sporadic T-cell leukaemia

scientific article published on September 1, 1997

HVCN1 modulates BCR signal strength via regulation of BCR-dependent generation of reactive oxygen species

scientific article

The CAMPATH-1 antigen (CDw52)

scientific article published on 01 March 1990

Recurrent involvement of the REL and BCL11A loci in classical Hodgkin lymphoma.

scientific article

Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion.

scientific article published on 29 October 2007

Humanized CD52 monoclonal antibody campath-1H as first-line treatment in chronic lymphocytic leukaemia

scientific article published on 01 April 1996

A genome-wide association study identifies multiple susceptibility loci for chronic lymphocytic leukemia

scientific journal article

Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol

scientific article published on 08 April 2010

Five members of the CEBP transcription factor family are targeted by recurrent IGH translocations in B-cell precursor acute lymphoblastic leukemia (BCP-ALL).

scientific article

Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia.

scientific article published in October 2002

Novel markers of normal and neoplastic human plasmacytoid dendritic cells

scientific article published on 24 January 2008

Transformation of follicular lymphoma to diffuse large cell lymphoma is associated with a heterogeneous set of DNA copy number and gene expression alterations

scientific article published on 24 October 2002

Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H

scientific article published on 01 February 1998

Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results.

scientific article

MALT1 is deregulated by both chromosomal translocation and amplification in B-cell non-Hodgkin lymphoma

scientific article

Apoptosis induced by histone deacetylase inhibitors in leukemic cells is mediated by Bim and Noxa.

scientific article published on 24 May 2007

Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies.

scientific article

Inhibition of Histone Deacetylase Class I but not Class II Is Critical for the Sensitization of Leukemic Cells to Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand–Induced Apoptosis

article by Satoshi Inoue et al published 1 July 2006 in Cancer Research

A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies

scientific article published on 5 November 2015

Transcriptional silencing of Polo-like kinase 2 (SNK/PLK2) is a frequent event in B-cell malignancies.

scientific article published on 13 September 2005

Cyclin D3 is a target gene of t(6;14)(p21.1;q32.3) of mature B-cell malignancies

article

Conformational change and mitochondrial translocation of Bax accompany proteasome inhibitor-induced apoptosis of chronic lymphocytic leukemic cells.

scientific article published in May 2003

Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial

scientific article published on 22 October 2012

TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies

scientific article published on 01 December 2005

Eμ/miR-125b transgenic mice develop lethal B-cell malignancies.

scientific article published on 8 July 2011

Characterization of 8p21.3 chromosomal deletions in B-cell lymphoma: TRAIL-R1 and TRAIL-R2 as candidate dosage-dependent tumor suppressor genes.

scientific article

A novel paradigm for rapid ABT-737-induced apoptosis involving outer mitochondrial membrane rupture in primary leukemia and lymphoma cells.

scientific article

ABT-199 selectively inhibits BCL2 but not BCL2L1 and efficiently induces apoptosis of chronic lymphocytic leukaemic cells but not platelets.

scientific article

Comprehensive whole genome array CGH profiling of mantle cell lymphoma model genomes.

scientific article published on 30 June 2004

A B-cell epigenetic signature defines three biologic subgroups of chronic lymphocytic leukemia with clinical impact.

scientific article published on 25 August 2014

Protein profiling of plasma membranes defines aberrant signaling pathways in mantle cell lymphoma.

scientific article published on 2 April 2009

Barriers to effective TRAIL-targeted therapy of malignancy

scientific article published on 01 October 2007

Human telomeres that carry an integrated copy of human herpesvirus 6 are often short and unstable, facilitating release of the viral genome from the chromosome

scientific article published on 19 September 2013

A high-density SNP genomewide linkage scan for chronic lymphocytic leukemia-susceptibility loci

scientific article published on 2 August 2005

Recurrent mutation of JAK3 in T-cell prolymphocytic leukemia

scientific article published on 21 January 2014

Loss of a novel tumor suppressor gene locus at chromosome 8p is associated with leukemic mantle cell lymphoma

scientific article published on 01 December 2001

Subcutaneous CAMPATH-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia

scientific article published on 01 March 1997

pH regulation and beyond: unanticipated functions for the voltage-gated proton channel, HVCN1

scientific article published on October 18, 2010

TRAIL signals to apoptosis in chronic lymphocytic leukaemia cells primarily through TRAIL-R1 whereas cross-linked agonistic TRAIL-R2 antibodies facilitate signalling via TRAIL-R2.

scientific article

Identification of Thr29 as a critical phosphorylation site that activates the human proton channel Hvcn1 in leukocytes

scientific article

List of works by Martin Dyer

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity

Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells

Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia

A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia

The BCL11 gene family: involvement of BCL11A in lymphoid malignancies

The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.

REMISSION INDUCTION IN NON-HODGKIN LYMPHOMA WITH RESHAPED HUMAN MONOCLONAL ANTIBODY CAMPATH-1H

Different forms of cell death induced by putative BCL2 inhibitors.

Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk

CARD9 is a novel caspase recruitment domain-containing protein that interacts with BCL10/CLAP and activates NF-kappa B

Clustering of missense mutations in the ataxia-telanglectasia gene in a sporadic T-cell leukaemia

HVCN1 modulates BCR signal strength via regulation of BCR-dependent generation of reactive oxygen species

The CAMPATH-1 antigen (CDw52)

Recurrent involvement of the REL and BCL11A loci in classical Hodgkin lymphoma.

Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion.

Humanized CD52 monoclonal antibody campath-1H as first-line treatment in chronic lymphocytic leukaemia

A genome-wide association study identifies multiple susceptibility loci for chronic lymphocytic leukemia

Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol

Five members of the CEBP transcription factor family are targeted by recurrent IGH translocations in B-cell precursor acute lymphoblastic leukemia (BCP-ALL).

Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia.

Novel markers of normal and neoplastic human plasmacytoid dendritic cells

Transformation of follicular lymphoma to diffuse large cell lymphoma is associated with a heterogeneous set of DNA copy number and gene expression alterations

Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H

Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results.

MALT1 is deregulated by both chromosomal translocation and amplification in B-cell non-Hodgkin lymphoma

Apoptosis induced by histone deacetylase inhibitors in leukemic cells is mediated by Bim and Noxa.

Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies.

Inhibition of Histone Deacetylase Class I but not Class II Is Critical for the Sensitization of Leukemic Cells to Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand–Induced Apoptosis

A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies

Transcriptional silencing of Polo-like kinase 2 (SNK/PLK2) is a frequent event in B-cell malignancies.

Cyclin D3 is a target gene of t(6;14)(p21.1;q32.3) of mature B-cell malignancies

Conformational change and mitochondrial translocation of Bax accompany proteasome inhibitor-induced apoptosis of chronic lymphocytic leukemic cells.

Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial

TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies

Eμ/miR-125b transgenic mice develop lethal B-cell malignancies.

Characterization of 8p21.3 chromosomal deletions in B-cell lymphoma: TRAIL-R1 and TRAIL-R2 as candidate dosage-dependent tumor suppressor genes.

A novel paradigm for rapid ABT-737-induced apoptosis involving outer mitochondrial membrane rupture in primary leukemia and lymphoma cells.

ABT-199 selectively inhibits BCL2 but not BCL2L1 and efficiently induces apoptosis of chronic lymphocytic leukaemic cells but not platelets.

Comprehensive whole genome array CGH profiling of mantle cell lymphoma model genomes.

A B-cell epigenetic signature defines three biologic subgroups of chronic lymphocytic leukemia with clinical impact.

Protein profiling of plasma membranes defines aberrant signaling pathways in mantle cell lymphoma.

Barriers to effective TRAIL-targeted therapy of malignancy

Human telomeres that carry an integrated copy of human herpesvirus 6 are often short and unstable, facilitating release of the viral genome from the chromosome

A high-density SNP genomewide linkage scan for chronic lymphocytic leukemia-susceptibility loci

Recurrent mutation of JAK3 in T-cell prolymphocytic leukemia

Loss of a novel tumor suppressor gene locus at chromosome 8p is associated with leukemic mantle cell lymphoma

Subcutaneous CAMPATH-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia

pH regulation and beyond: unanticipated functions for the voltage-gated proton channel, HVCN1

TRAIL signals to apoptosis in chronic lymphocytic leukaemia cells primarily through TRAIL-R1 whereas cross-linked agonistic TRAIL-R2 antibodies facilitate signalling via TRAIL-R2.

Identification of Thr29 as a critical phosphorylation site that activates the human proton channel Hvcn1 in leukocytes